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Abstract
Background: Small molecules that bind reversibly to DNA are among the antitumor drugs
currently used in chemotherapy. In the pursuit of a more rational approach to cancer
chemotherapy based upon these molecules, it is necessary to exploit the interdependency between
DNA-binding affinity, sequence selectivity and cytotoxicity. For drugs binding noncovalently to
DNA, it is worth exploring whether molecular descriptors, such as their molecular weight or the
number of potential hydrogen acceptors/donors, can account for their DNA-binding affinity and
cytotoxicity.
Results: Fifteen antitumor agents, which are in clinical use or being evaluated as part of the
National Cancer Institute’s drug screening effort, were analyzed in silico to assess the
contribution of various molecular descriptors to their DNA-binding affinity, and the capacity of
the descriptors and DNA-binding constants for predicting cell cytotoxicity. Equations to predict
drug-DNA binding constants and growth-inhibitory concentrations were obtained by multiple
regression following rigorous statistical procedures.
Conclusions: For drugs binding reversibly to DNA, both their strength of binding and their
cytoxicity are fairly predicted from molecular descriptors by using multiple regression methods.
The equations derived may be useful for rational drug design. The results obtained agree with that
compounds more active across the National Cancer Institute’s 60-cell line data set tend to have
common structural features.
Background
DNA-binding molecules represent a valuable portion of the clinically useful antitumor drugs [1,
2]. Most of the drugs than bind noncovalently to DNA, such as actinomycin D and several
anthracyclines [1, 3], interact selectively with the nucleic acid along the minor groove or by
intercalation. The binding mode depends on structural features of these molecules and on the
DNA sequences they recognize [4-6]. The strength of reversible binding to DNA can be
quantified for any drug by means of the equilibrium binding constant (Keq). In the determination
of the binding constant, the primary results obtained from whatever the technique used and the
analysis of the data are not straightforward as there is no a single protocol that might be applied to
every ‘binding problem’ [7]. Therefore, DNA-binding data, which may be used to correlate
noncovalent drug-DNA interactions with cytotoxicity data, should be regarded as ‘approximate
values’ compared to the more accurate measurements that are available on some physicochemical
molecular descriptors for these molecules, such as molecular weight, hydrophobicity or the
number of hydrogen bond donors.
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The analysis of antitumor drugs based on an evaluation of cytotoxicity data may provide new
insights into their mechanism of action [2, 8]. The 60 human cancer cell lines used in the
screening of compounds at the National Cancer Institute (NCI) provide basically the GI50 (50%
growth-inhibitory concentration) as an index of cytotoxicity or cytostasis. The NCI cell line data
set is a publicly available database that contains cellular assay screening data for over 40000
compounds tested in 60 human tumor cell lines (referred to hereafter as the NCI-60 cell lines).
The database also contains microarray gene expression data, thus providing an excellent
information resource particularly for the analysis of links between chemical, biological, and
genomic information [2, 8-11].
While it is worth characterizing cancer cells to predict chemosensitivity to any particular
drug [12], and to link changes in gene expression to cytotoxicity [8, 13-15] it is also of utmost
importance a deeper understanding of the mechanism of action of drugs, which includes the
dissection of forces driving their noncovalent binding to DNA, and to use this information to help
in the development of new anti-cancer agents with higher activity [9, 16, 17].
This paper presents the analysis of the relationship between various physicochemical
descriptors for drugs, and uses these descriptors to predict both the strength of noncovalent
binding to DNA and the biological activity. Although there are previous studies considering that
large and more complex molecules are more potent antitumor agents [9], there is no clear
association between biological potency and the strength of reversible binding to DNA, while
there are some examples illustrating that changes in DNA binding among structurally related
molecules can be accompanied by abrupt changes in biological activity [18]. The strategy
followed here utilizes DNA-binding constants taken from the ample, and sometimes
contradictory, bibliography on DNA-binding drugs. The Keq values, shown as logarithmic-
transformed values logKeq in Table 1, were selected following the same criteria used elsewhere
[5] to analyze the signature for drug-DNA binding modes.
It was feasible to achieve the required robustness for an in silico study based on a relatively
small sample population by using different and, to some extent, complementary approaches under
a careful statistical control. It was, therefore, possible to derive equations to predict the strength
of binding to DNA and the biological activity (cytotoxicity) by multiple regression methods using
a combination of structure-based molecular descriptors and some other physicochemical
descriptors as predicting variables. Moreover, factor analysis was used to uncover the latent
structure (dimensions) of the molecular descriptors. Principal component analysis is exposed as a
valuable tool for predicting of redundancy of descriptive elements in drug design. Both the
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strength of noncovalent binding to DNA and cytotoxicity might be predicted, even though not
perfectly, from molecular descriptors.
Methods
Noncovalent DNA-binding drugs: A database of molecular descriptors and growth inhibition
response
The antitumor drugs used in the present analysis were selected by two complementary criteria.
First, they are drugs binding noncovalently to DNA whose binding affinity, measured as the
equilibrium binding constant Keq, as well as their mechanism of binding —intercalation or
minor-groove binding— have been fully established previously. Second, their cytotoxicity assays
using the NCI-60 cell lines are publicly available through the Developmental Therapeutics
Program NCI/NIH database at: http://dtp.nci.nih.gov/dtpstandard/dwindex/index.jsp (cancer
screen data, August 2008). For the sake of convenience, GI50, the 50% cancer cell growth
inhibition concentration for any particular cell line, a measure of cytotoxicity or cytostasis, is
used to indicate the –log(GI)50 provided by the database. The GI50 measures shown in Table 1 are
the arithmetic mean of the GI50 measurements in these 60 cell lines.
Common molecular descriptors for all the drugs were retrieved from the PubChem
compound web site: http://pubchem.ncbi.nlm.nih.gov. Lipinski’s scores were retrieved from the
ChemDB (NIAID) database (http://chemdb2.niaid.nih.gov). The drug-DNA equilibrium binding
constants (Keq) were obtained from a survey of the vast, and, sometimes, contradictory
information found in the bibliography (see Results). The equilibrium binding constants entered in
Table 1 correspond almost exclusively to those acquired under similar experimental conditions:
20-25 °C, pH 7 and 150-200 mM NaCl, in accordance with an uniform criteria used elsewhere to
establish a thermodynamic signature for the drug-DNA mode of interaction [5]. Throughout this
paper the logarithmic-transformed values (logKeq) are used for the convenience of normalization
of the data.
Fifteen antitumor drugs (Table 1 and Fig. 1), most of them in clinical use, were deemed to
achieve the criteria required to enter the present study.
Correlation and Multiple Regression
Most statistical calculations were carried out using the SPSS v.13.0.1 package (SPSS Inc.,
Chicago, IL). The normality (normal distribution) of the data was analyzed by the Shapiro-Wilk
test, which is especially suitable for analyzing samples containing a small number of variables
[19]. Both the Pearson and Spearman’s ρ correlation coefficients (one tailed tests) have been
calculated among the different molecular descriptors. Pearson coefficients require assuming a
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normal distribution of the sample, while the Spearman’s ρ is a non-parametric measure. The
actual p values are usually indicated for the different statistic analyses.  
 Multiple regression was used to predict Keq from the molecular descriptors described in the
legend to Table 1. Multiple linear regression benefits from a well-developed mathematical
framework that yields unique solutions and exact confidence intervals for regression coefficients
[20]. As the first choice, the regression procedure followed was stepwise selection (criteria used:
probability-of-F-to-enter ≤ 0.050, probability-of-F-to-remove ≥ 0.100), although other available
methods as entry and backward were also used to reach the better, statistically significant,
estimation of logKeq. Multiple regression was also used to predict GI50, using the same molecular
descriptors plus Lipinski’s scores and logKeq values as additional variables.
The model output, generated by the SPSS software package, provides several parameters that
were used to check the reliability of the analysis, such as the correlation coefficient (r), r2 that
indicates the percentage of the variation in logKeq (or GI50) that can be explained by the
regression, and the adjusted r2 (AdR2) that is the r2 corrected for the number of predictors.
AdR2 was determined by the following equation:
AdR2 = 1 − (1 − r 2 ) n− 1
n− k −1
in which n = number of cases (drugs) and k = number of variables (descriptors)
AdR2 was computed to avoid an overestimation in predicting r2 due to the few cases (15
drugs) tested relative to the number of variable (6 molecular descriptors) —up to 8 variables
when Lipinski’s rule scores and logKeq values were introduced in the analyses of GI50, see
results—.
Multicollinearity
Multicollinearity, also known as collinearity, arises when a high degree of correlation (either
positive or negative) exists between two or more independent variables. Because multicollinearity
means redundancy in the molecular descriptors to predict logKeq or GI50, its presence was
detected by determining the variance inflation factor (VIF), which can be computed from
individual r2 —distinct from the overall r2 of the model—using the following equation:
VIF = 1/(1 - r 2 )
When variables are collinear VIF is higher than 1. A VIF of 4 and above was used to detect a
multicollinearity problem (corresponding to r2 values greater than 0.75) and used to eliminate the
corresponding molecular descriptors from predictive equations.
Hierarchical cluster analysis of molecular descriptors and DNA-binding drugs
Cluster analysis was performed with the SPSS software, using a single linkage (agglomeration)
algorithm method and Pearson correlation coefficients. Dendrograms showing hierarchical
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clustering are presented in terms of similarities between cases (DNA-binding drugs) or variables
(molecular descriptors).
Principal Component Analysis
Principal component analysis was undertaken as a way of identifying patterns in data, and
expressing them in such a way as to highlight their similarities and differences. Principal
component analysis extracted factors on the basis of the correlation between the six molecular
descriptors in Table 1 and logKeq. For GI50 analysis, logKeq and Lipinski’s scores (Table 1) were
used as additional predictor variables.
Principal component with eigenvalues of 2 were retained and orthogonally rotated using the
Varimax method — the point was to minimize the complexity of the component while ensuring
that the molecular descriptors were uncorrelated—. Descriptors with loadings of ≥ 0·25 or
≤ − 0·25 were considered as significant contributors. Factor scores were saved for each principal
component, and used to obtain graphic representations of drug’s scores, on 2D principal
component plots.
Results
Drugs that bind reversibly to DNA can be characterized by common molecular descriptors, as
well as by their DNA-binding constant
Table 1 shows six common molecular descriptors, XlogP, molecular weight (Mw), number of
potential hydrogen bond acceptors (HbA), potential hydrogen bond donors (HbD), polar surface
area (PSA) and complexity. The complexity rating of a compound is the rough estimate of how
complicated a structure is, seen from both the point of view of the elements contained and the
displayed structural features including symmetry. The complexity values, computed using the
Berz/Hendrickson/Ihlenfeldt formula, were retrieved from the PubChem compound web site:
http://pubchem.ncbi.nlm.nih.gov. Table 1 also presents the equilibrium DNA binding constant for
fifteen drugs, retrieved from the bibliography [4, 5, 16, 21-31] (the values of Keq have been
transformed to logKeq in the sake of data normalization). Table 1 also displays the values of the
Lipinski’s score (a measure of bioavailability [32]), and the GI50, which is a measure of the
cytotoxicity or cytostasis induced by the different drugs [2] —it corresponds to the negative
logarithm of the drug concentration that inhibits cell growth—. Table 1 contains molecules
binding to DNA reversibly [4], yet some of them are also classified as topoisomerase II poisons,
or they are known to be involved in reactions leading to DNA cleavage. The set of DNA-binding
drugs encloses intercalators, the bis-intercalator echinomycin, and some minor-groove binders.
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The number of variables (molecular descriptors) and drugs that accomplished the
prerequisites to enter the study was rather small; thereby normality of the sample distribution
could be compromised. According to the Shapiro-Wilk normality test (Table 2), only Mw, and
HbD departed significantly from normal distribution (p > 0.01). Furthermore, other precautions
needed in a statistical analysis of small populations were undertaken, and they are indicated in the
relevant place in the text.
 The fifteen drugs described in Table 1 were tested as three subsets aimed at helping to parse
the potential of molecular descriptors for predicting logKeq values. The first set contemplates all
the DNA-binding drugs, while the other sets correspond to the intercalators (bis-intercalating
echinomycin was not considered a member of this subset), and to DNA-binding drugs that had
been organized into self-organizing maps (SOM) as belonging to the ‘M-region’ (so, named here
as ‘M-region’ compounds) [9]. ‘M region’ compounds possess an outstanding cytotoxic, or
cytostatic, activity (high GI50 values) and relatively larger PSA and Mw compared to other
antitumor drugs analyzed in the NCI-60 cell lines [9]. Drugs belonging to this SOM region were
obtained online by using the 3D Mind tools at: http://spheroid.ncifcrf.gov/spheroid/default.htm.
They are actinomycin D, chromomycin, daunorubicin, doxorubicin, echinomycin, elsamicin A,
mithramycin A and mitoxantrone.
Correlations between the drug binding constant (logKeq) and the different molecular
descriptors were calculated by using two different coefficients: the Pearson correlation
coefficient, which is a parametric statistic, and the non-parametric Spearman’s ρ correlation
coefficient, which might be more reliable for the molecular descriptors that did not show a normal
distribution (Table 3). The Pearson and Spearman’s ρ correlations calculated between each
molecule descriptors plus logKeq and GI50 values are shown, together with the significance
levels, in Additional Files 1 and 2, respectively.
Significant correlations between logKeq and several molecular descriptors were established
according to both the Pearson and Spearman’s ρ coefficients (Table 3) —see also Additional
Files 1 and 2—. These results indicated that it was reliable to use the more robust parametric tests
throughout the present study despite the, from a statistical point of view, small size of the sample
analyzed —when corrections for small sample were available they were thoroughly used—, or
the departure from normality of a few parameters. In general, there was a clear correspondence
between the correlation values obtained by using either coefficient, yet the actual p values
differed (Table 3). The molecular descriptors that correlated better, either positively or negatively,
with logKeq were not the same when the fifteen drugs were evaluated together, or the correlations
were calculated for ‘intercalators’ and ‘M-region’ compounds respectively. According to the
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Pearson correlation coefficients, when all the drugs were analyzed together there was a negative
correlation with XlogP (p < 0.05) but also with Mw and complexity, although with p < 0.1 (Table
3). According to the Spearman’s ρ, only XlogP correlated negatively with logKeq (p < 0.1). For
the DNA intercalators, both coefficients showed a negative correlation between logKeq and
XlogP; while the Spearman’s ρ also indicated a significant positive correlation with HbD (Table
3). The number of molecular descriptors that correlated significantly with logKeq was clearly
higher when the more active ‘M region’ compounds were studied (Table 3). Both coefficients
revealed significant correlations between logKeq and four molecular descriptors: Mw, HbA, PSA
and complexity (p < 0.01). Nevertheless, some of these descriptors were also highly correlated
among them, and therefore there are grounds for considering that any intention of deriving
equations to predict logKeq for any DNA-binding molecule based upon a combination of these
molecular descriptors should not disregard that they can contain redundant information. The only
molecular descriptor that seemed to be relatively independent of the other descriptors was XlogP,
tentatively because it is a molecular descriptor for hydrophobicity almost independent of the size
of the molecules.
Drug-DNA binding constants might be predicted from a set of molecular descriptors
Multiple linear regression calculations were used to derive equations to predict logKeq for drugs
binding reversibly to DNA by using the set of molecular descriptors shown in Table 1. If these
equations are to be used in drug analysis, a multiple regression approach would require to
consider the presence of redundant information among the molecular descriptors, because several
molecular descriptors showed a fair correlation with logKeq (Table 3), thus redundancy
(multicollinearity, see Methods) had to be avoided. The number of cases (i. e., noncovalent DNA-
binding drugs) should substantially exceed the number of predictor variables to be used in a
multiple regression analysis (one rule of thumb is to have at least five times more cases as
predictor variables). At first glance, this is a condition that seems impossible to meet here.
Nevertheless, since redundancy may be eliminated, as shown below, the number of variables
(molecular descriptors) was reduced; thereby the variables to cases ratio became acceptable.
Table 4 presents the equations obtained by multiple linear regression that predict logKeq by
using some of the molecular descriptors as variables. All the equations were derived following
two criteria. First, they contained predictors in absence of multicollinearity, thus avoiding
redundancy owing to the high correlation between some of the molecular descriptors. The VIP
(variance inflation factor) was used to eliminate any multicollinearity —see Methods and
Additional File 3—, which explains the statistic details. Second, they were statistically significant
according to an ANOVA test (Table 4, and Additional File 3). When the 15 drugs were analyzed
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together, logKeq values were better predicted by XlogP (the correlation was negative), yet the
polar surface area (PSA) could also participate (p < 0.1; Table 4 and Fig. 2A). The prediction of
logKeq using these molecular descriptors was low 36% according to the r2 values, corresponding
to about 26% when an adjusted r2, which accounts for the small size of the sample, was used
(AdR2 in Table 4) and barely significant (Table 4). Much better predictions of logKeq were
obtained when drugs were considered as the subsets ‘intercalators’ and ‘M-region compounds’
described above. For intercalators, about 44% (37% using the adjusted parameter) of the logKeq
values were explained by XlogP (p < 0.05; Table 4 and Fig. 2A). The better prediction of logKeq
was obtained for the drugs included in the ‘M-region’, for which two equations were derived
from multiple correlation models (ANOVA test, p ≤ 0.002), with a prediction reaching more than
90% (almost the same value was observed when the AdR2 was considered, Table 4). It is
noteworthy that for this particular set of drugs XlogP contribution appeared to be less important
than the HbA and HbD values. This observation is in keeping with the ranks of molecular
descriptors and mean GI50 used to define the ‘M-region’ in SOM analysis [9] (see also Fig. 2A).
Hierarchical cluster analysis builds groups of molecular descriptors and DNA-binding drugs
based on their similarity
A hierarchical clustering analysis of the different molecular descriptors based on the Pearson
correlation coefficient was used to build groups of molecular descriptors showing close
physicochemical properties. The dendrograms shown in Fig. 2B indicated that among the
molecular descriptors there were only two independent predictors: XlogP (a round measure of
lipophilicity or hydrophobicity) and molecular size, which clustered at larger distances. One of
the clusters revealed the proximity among the variables that appear to depend on the molecule
size, such as Mw or PSA, while the other two parameters XlogP and logKeq only clustered with
them at large distances. This clustering visually showed that the different parameters were highly
correlated, the exception being XlogP (Fig. 2B). These results were consistent with previous
reports that used a larger data set that included drugs with multiple mechanisms of action [9].
This coincidence, which occurred regardless of the sample size, may be considered as an indirect
proof of the robustness of the present approach using a smaller sample population.
Moreover, hierarchical analysis was used to classify the different drugs into relatively
homogeneous groups within themselves and heterogeneous between each other, on the basis of
the Pearson correlations between molecular descriptors (Fig. 2C). Dendrograms, showing the
relationship among the six molecular descriptors used to predict logKeq for all the DNA-binding
drugs are shown in Fig. 2C, with connection lines further to the right indicating more distance
between drugs and clusters. This hierarchal classification grouped together molecules with similar
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structures, such as the anthracyclines doxorubicin, daunorubicin and epirubicin, while the more
complex actinomycin D and echinomycin were also brought together in a different cluster, the
latter clustering next to other large molecules, such as bleomycin and the structurally related
aureolic acid antibiotics mithramycin A and chromomycin. The minor-groove binder distamycin
clustered with the anthracyclines (Fig. 2C), in keeping with that all these molecules showed
similar values in several parameters, which included logKeq and complexity (Table 1).
Principal component analysis discovers and summarizes patterns of intercorrelation among
molecular descriptors
The presence of multicollinearity in the multiple regression analysis raised a question on whether
some of the parameters used in the analysis of drug’s activity endure redundant information that
may be reduced to a few key molecular descriptors conveying all the structural information
required for drug design. A way to identify underlying variables (factors) is provided by principal
component analysis, see Methods. The variables (molecular descriptors) for the fifteen
noncovalent DNA-binding drugs were analyzed, using three separate computations corresponding
to the three subsets of drugs described above.
Fig. 3 shows the results of a principal component analysis, in which the molecular descriptors
were plotted on the first two components. In principal component analysis the measure of the
percent of variance in a given variable explained by all the factors is known as communality.
Communalities corresponding to the different principal component analysis are shown as
supplementary data (Additional File 4), which also presents other statistic details of the principal
component analysis. For all drugs, the extracted communalities were, in general, over 90%, which
means that most of the percent of variance in a given molecular descriptor was explained by the
factors (components) extracted. When all the drugs were considered together the first principal
component explained 74.22% of total variance, while 20.13% was explained by the second
component (Fig. 3A). In summary, the two principal component models were enough to
accurately describe the data, since they explained 94.35% of the variance. Component 1 can be
considered to reflect the “molecular size” while component 2 would represent a “hydrophilicity-
hydrophobicity” axis, with XlogP clearly loading in the hydrophobic part of it. Graphic
representation of the scores obtained by principal component analysis offered a direct visual
identification of some common features of the drugs (Fig. 3B). For example, structurally-related
drugs, such as the anthracyclines, clustered together in the same regions of the plot. Besides, the
larger molecules also clustered nearby (echinomycin, actinomycin D), or also the smaller ones
(ethidium and m-AMSA). There were some differences in the exact location (score) on the
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graphic representation depending on the subset of data used: all drugs (Fig. 3B), intercalators
(Fig. 3D) or ‘M-region’ compounds (Fig. 3F)).
The larger bleomycin, mithramycin A and chromomycin (Table 1) were located in a region
corresponding to the positive values of the first component, on account of their “big size”
compared to the relatively smaller doxorubicin and daunorubicin (Fig. 3B). Figs. 3C and 3D show
the principal component analysis for the set of DNA-intercalating drugs, for which the principal
component explained 77.74% of the variance, and 17.35% was explained by the second
component, with a total 95.09% of variance explained by both factors. Principal component for
the ‘M-region’ compounds (Figs. 3E and 3F) were 64.11% and 29.87% respectively, with a
93.98% of the total variance explained. The number of potential hydrogen donors (HbD) had a
loading value much closer to the hydrophilic factor in this component, opposite to XlogP loading
(Fig. 3E). An elevated relevance of the number of potential hydrogen bonding in drugs belonging
to the ‘M-region’ subset was in concordance with the importance given to them as a source of
DNA-binding specificity [4, 5].
DNA-binding constants and a combination of molecular descriptors might be used to estimate
the cytotoxicity (GI50 values) of drugs binding noncovalently to DNA
After obtaining equations that predict logKeq from the different molecular descriptors, we should
consider whether a correspondence exists between the strength of noncovalent binding to DNA
and the cytotoxicity or cytostasis measured as the GI50 values. At this point, the Lipinski’s scores
[32] (Table 1), an additional descriptor of biological activity for drugs (also known as the rule-of-
five), was added for the following calculations.
For the complete set of DNA binding drugs a small negative and nonsignificant correlation
was found between GI50 and logKeq (Pearson correlation coefficient: -0.277 (p = 3.17 x 10-1)),
which for the more potent ‘M-region’ compounds was -0.822 (p = 1.51 x 10-1)). However, the
correlation was positive, yet barely significant, when the subset of intercalators was considered
(0.413; p = 1.17 x 10-1). Although, all these correlations were within the limits of being of
random occurrence, it is noteworthy that cytotoxicity was not positively related to logKeq, except
for the intercalating agents. Indeed, the ‘M-region’ encompasses several intercalators (Fig. 2a and
Table 1), which suggested that any interpretation based solely on the correlation between any pair
of descriptors has to be evaluated with caution. Complexity, which as explained above, is a rough
estimate of how complicated a structure is (Table 1), was significantly and positively correlated
with GI50 for “all drugs” (0.591; p = 2.0 x10-2), intercalators (0.435; p = 1.04 x10-2) and ‘M-
region’ compounds (0.984; p = 5.23 x 10-6). A further analysis of the potential effect of the
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equilibrium binding constant on the prediction of GI50 was undertaken by other approaches
described below.
Multiple regression was used to derive equations to predict GI50, avoiding the problems of
multicollinearity. Table 5 shows the equations calculated for either set of drugs (“all” drugs,
intercalators and ‘M-region’ compounds). Statistical details about the multiple regression analysis
are shown as supplementary data (Additional File 5), including the VIF (variance inflation factor)
values used to detect multicollinearity. Using the entry method, see Methods, logKeq was
included in the predicting equations, taking special care that adding this new variable did not
violate the absence of multicollinearity. When the 15 DNA-binding drugs were analyzed together
the multiple linear regression analysis excluded logKeq as a variable, following the enter/remove
criteria outlined in Methods. Much better prediction for GI50 was reached in the analysis of the
‘intercalators’ and ‘M-region’ subsets, and the predicting equations contained logKeq as a
variable (Table 5). For the ‘M-region’ compounds, about 96% of GI50 value was predicted
multiple regression (Table 5 and Fig. 4A). Unexpectedly, Lipinski’s scores (Table 1) did not
participate significantly in any of the equations derived to predict GI50 values. The main cause for
this was multicollinearity.
Complexity was the main predictor for cytotoxicity (GI50 values, Table 5). This observation
was consistent with that more complex molecules would tend to be more potent inhibitors of cell
growth [9], while the chance of violating Lipinski’s rule is enhanced for large molecules [32].
However, a comparison between Tables 4 and 5 uncovered that complexity was not a relevant
variable in the equations aimed at predicting the DNA-binding constant (logKeq) described
above. Complexity was excluded from the equations used to predict logKeq, regardless of its
importance in predicting GI50 values, because it showed a significant multicollinearity with other
parameters related to size. Consistently, complexity loaded close to Mw in the principal
component loading plots (Fig. 3).
A hierarchical clustering of all the drugs based on the Pearson correlation coefficients (Fig.
4B) rendered two main clusters that separate the molecules with higher complexity from the rest
of compounds. Although at first glance complexity may benefit from a larger size, it also
considers other structural features including symmetry (Table 1). Some degree of coherent
clustering was expected for molecules related by chemical structure, thus structurally-related
molecules clustered nearby, such as the anthracyclines and the intercalator elsamicin A (Figs. 1
and 4B).
Principal component analysis was used to further disclose the relationship between GI50,
logKeq and common molecular descriptors. As seen, the first principal component (Fig. 4C)
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separated all the size-related descriptors from Lipinski’s scores, which evaluates large molecules
negatively [32]. The principal component analysis of the more biologically-active ‘M-region’
compounds produced a correlation matrix that was not positive definite, together with a low
extraction of Lipinski’s score (46 % only; see Additional File 6), thus an additional principal
components analysis was performed in which Lipinski’s scores were not considered. While the
reasons that could render a matrix that was not positively definite are diverse and difficult to
delineate, removing Lipinski’s score in the analysis was enough to render a meaningful
correlation matrix, perhaps indicating that this predictor was essentially not independent of the
other molecular descriptors. The extraction of two components using principal component
analysis explained about 87%, 88% and 94% of the total variance for all the drugs, intercalators
and ‘M-region’ compounds respectively (Additional File 6). It is noteworthy that the
anthracyclines, which are a well referenced group of active antitumor drugs [3] clustered near the
negative region of the second principal component in the region of logKeq loading (cf. panels C
and D in Fig. 4). The huger molecules scored in the region corresponding to the loadings of
complexity and XlogP (up-right quadrant in Fig. 4C), while the smaller ethidium and m-AMSA
scored consistently in the plot region with higher XlogP and Lipinski loadings.
Discussion
There is an increasing interest in interfacing the studies on drug cytotoxicity based on the NCI’s
tumor screening panels with gene expression databases and the mechanisms of drug action, cell
sensitivity and resistance [8, 14]. These complementary approaches should provide clues about
the mechanisms of some molecules, which ultimately can be developed as antitumor agents [10,
14, 15]. Drugs binding noncovalently to DNA have been in cancer treatment since the 60’s, and a
detailed structural and functional data on these molecules is available [4], including quantitative
data on their binding to DNA as well as the GI50 determined in the NCI-60 cell lines. These data
sources evidence the selectivity and relative effectiveness of such drugs as anti-cancer agents [1,
8, 14], which in a few cases has brought about the development of new clinically useful
derivatives, such as the anthracycline epirubicin [3].
We can intuitively consider that a certain relationship should exist between the affinity of
some drugs for binding to certain DNA sequences and the mechanisms of action, including their
cytotoxicity. Hence, it seems possible to facilitate the development of new drugs through a better
knowledge of the molecular descriptors that may participate in the strength of binding to DNA. It
is anticipated that any prediction of biological activity using physicochemical descriptors is open
to some margin of error because there are other aspects that participate in cytotoxicity, such as
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pharmacokinetics (for example, whether the drugs can easily cross the cell membrane, or overtake
a multidrug resistance phenotype). The relation between the capacity of a certain drugs for
binding DNA and their biological activity is made evident by the correlation found between
physicochemical and biological data for some m-AMSA and actynomycin D analogs, which have
been developed from QSAR studies [18, 33], and also because DNA-binding drugs may act
considered to act by altering gene transcription through the inhibition of the interactions between
DNA and certain transcription factors [1, 34, 35]. Besides some o the drugs shown in Table 1 are
also regarded as topoisomerase II poisons, seemingly as a results of their interference with the
DNA binding sites for the enzyme, an aspect that is only indirectly addressed here in terms of the
drug’s equilibrium binding constants. Nevertheless, this makes an interesting point, because it
may, for example, explain why m-AMSA is much potent antitumor agent than ethidium (cf. their
GI50 values in Table 1) even though most of their molecular descriptors are very similar (Table 1).
Moreover, m-AMSA is active while o-AMSA, which contains a methoxy group in the ortho
rather than in the meta position, is not [36] regardless of the higher DNA-binding constant of o-
AMSA [24]. The m-AMSA activity is explained by its direct interaction with topoisomerase II
[36]. In spite of this, the replacement of the acridine moiety with the analogous 2-oxo-2H-
pyrano[2,3-b]quinoline system drastically reduced both the anti-cancer activity and the
intercalation into DNA [37] in line with the correlation observed for intercalators between logKeq
and GI50.
The analysis presented here represents the first attempt at establishing the bases for a deeper
understanding of the links that appear to exist between antitumor activity and drug binding to
DNA by evaluating whether molecular descriptors can be used to define noncovalent drug-DNA
interactions. A clear correlation between logKeq and several molecular descriptors is evident
(Table 3). Among them, only XlogP is clearly and ‘independent’ descriptor, mostly because it is
the unique descriptor in Table 1 for which the molecular size is barely relevant (Figs. 3 and 4).
Although, the multiple linear regression method used here cannot capture nonlinear aspects
of the relation between logKeq or GI50 and the molecular descriptors, the approach used in this
paper may be replaced by any chosen nonlinear mathematical regression. Multicollinearity has
been considered scrupulously given the small number of both drugs and molecular descriptors,
thus its occurrence was used to eliminate redundancy in equations aimed at predicting logKeq
(Table 4) or GI50 (Table 5). The computations presented here disclosed that principal component
analysis is a rather strong tool for predicting the presence of redundancy in descriptive elements
during drug design, helping to clarify the relative importance of each molecular descriptor (Figs.
3 and 4). In general, it can be considered that large molecules, no matter whether they intercalate
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or not into DNA, may “benefit” of their complexity to become more cytotoxic (Table 1), while
several smaller intercalators, such as the anthracyclines, which bind tightly to DNA [16, 30], are
known useful antitumor agents, tentatively on account of their effects on gene transcription [13,
38]. The loadings of the different molecules in the principal component analysis (Fig. 4C) suggest
that diverse molecular descriptors, chiefly Keq and complexity (Table 5), would participate in the
final cytotoxic potential and its predictability.
Lipinski’s scores have been widely used as a predictor for bioavailability [32]. The Lipinski’s
rule-of-five states that small hydrophobic molecules should be better therapeutic agents. The
results presented here challenge this view in agreement with reports indicating that Lipinski’s
scores are not an appropriate molecular descriptor when dealing with large natural products [39],
as it is the case with most of the drugs analyzed here. A large set of the molecules shown in Table
1 violates several of the Lipinski’s rules, such as having molecular weights over 500 g.mol-1, or
hydrogen bond donor counts (HbD) higher than five.
In absence of Lipinski’s scores in the equations to predict GI50 (Table 5), complexity, a
measure of how complicated a molecule is (Table 1), emerged as a fundamental predictor for
biological activity, in keeping with the view that more complex molecules tend to be more potent
antitumor agents [2, 9, 16]. Among the more potent drugs analyzed here, those with GI50 ≥ 7,
only mitoxantrone has a Lipinski’s score higher than 2 (Table 1).
Equations obtained by multiple regression were significantly better at predicting logKeq or
GI50 for the M-region compounds (actinomycin D, chromomycin, daunorubicin, doxorubicin,
echinomycin, elsamicin A, mithramycin A and mitoxantrone) than for the subset of intercalators
or for the entire set of DNA-binding drugs. About 90% of the experimental logKeq and 95% GI50
were simulated even after correcting the results for the small sample population (AdR2 values
shown in Tables 3 and 4). In SOM the ‘M-region’ encompasses potent antitumor compounds [9],
some of them are DNA-binding drugs, which act mainly by interfering with DNA synthesis and
transcription, but it also contains other drugs of natural origin acting against the mitotic spindle,
such as taxanes [9].
A potential concern about the approach presented here was to establish the robustness of the
statistical tests that, of necessity, were employing a small number of cases (drugs), which
represent only about twice the number of variables (molecular descriptors). However, by using
both parametric and nonparametric statistic approaches, it has been possible to evaluate the
strength of noncovalent drug binding to DNA from common molecular descriptors, and to
established whether these molecular characteristics are correlated with their cytotoxic/cytostatic
activity in cells in culture. In addition, it will be opportune to link the predictions presented here
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with the analysis of changes in gene expression induced by those drugs since this may retrieve
genes that can be used as predictors of chemosensitivity [8, 11, 13, 40].
Target-specific drugs that bind reversibly to certain DNA sequences with high affinity have
been of outstanding interest in the development of new antitumor agents [16, 17, 41]. A main
conclusion of the present study is that both the strength of binding to DNA and drug cytotoxicity
are fairly predictable from molecular descriptors, in agreement with that compounds active across
the NI-60 cell lines tend to have common structural features [42].
Conclusions
For drugs binding reversibly to DNA, both their strength of binding and their cytoxicity may be
predicted from molecular descriptors by using multiple regression methods. Equations to predict
drug-DNA binding constants and growth-inhibitory concentrations were obtained by multiple
regression following rigorous statistical procedures. These equations may be useful for rational
drug design The results obtained agree with that compounds more active across de National
Cancer Institute’s 60 cell-line data set tend to have common structural features.
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LEGENDS TO FIGURES
Fig. 1. Molecular formulae of six of the noncovalent DNA-binding drugs used in the present
study.
The drugs displayed are characterized by their high activity in the NCI’s tumor screening panel.
Fig, 2. Common molecular descriptors and noncovalent binding to DNA.
(A) Predicted logKeq values obtained by multiple regression analysis using molecular descriptors
(Keq (cal)) are plotted together with experimentally calculated values (Keq (cal)) for the complete
set of drugs, intercalators and ‘M region’ compounds respectively. Equations used to calculate
logKeq are shown in Table 4. ACT (actinomycin D), BLEO (bleomycin), CHAR (chartreusin),
CRO (chromomycin), DAU (daunorubicin), DIST (distamycin), DOXO (doxorubicin), ECH
(echinomycin), ELSA (elsamicin A), EPI (epirubicin), ETH (ethidium), AMSA (m-AMSA),
MTA (mithramycin A), NETR (netropsin). (B) Dendogram showing average linkage hierarchical
clustering of six molecular descriptors for noncovalent DNA-binding drugs, based on the Pearson
correlation coefficients. Descriptors with higher similarity are clustered together. (C) Hierarchical
clustering applied to the 15 drugs binding reversibly to DNA (Table 1) on the basis of their
proximities. Connecting lines further to the right indicate more distance between clusters of either
molecular descriptors (B) or drugs (C).
Fig. 3 Principal component analysis of molecular descriptors for noncovalent DNA-binding
drugs.
Two-dimensional representation of loading values and factor scores on principal components 1
and 2 are shown in a rotated space. Component 1 may be labeled “molecular size” while
component 2 would be “hydrophilicity-hydrophobicity”, with XlogP clearly loading in the
hydrophobic part of the axis. Loadings are displayed side-by-side with a representation of the
factor scores for the different drugs on the two principal components. Graphical representations
correspond to the analysis of all fifteen noncovalent DNA-binding drugs (A) (B), intercalators
(C) (D), and the ‘M-region’ compounds (E) (F), respectively.
Fig. 4. Molecular descriptors and cell growing inhibition (GI50).
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(A) Plot comparing the GI50, retrieved from the NCI-60 cell lines (Table 1) and the values
calculated by multiple regression analysis (GI50 (obs)). Equations used to calculate GI50 are shown
in Table 5. The plot corresponds to the more active ‘M-region’ compounds. (B) Dendrograms
showing a hierarchical clustering of all DNA-binding drugs, which takes into account all the
descriptors, including logKeq and Lipinski’s scores. (C) Principal component analysis of
molecular descriptors plus logKeq and Lipinski’s scores for all the DNA-binding drugs, shown in
a rotated space; two-dimensional representation of loading values are shown (C), and the drugs
represented according to their factor scores in principal component analysis (D).
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Table 1. Molecular descriptors for noncovalent DNA-binding drugsa.
NSC
number
DNA binding Mw XlogP HbD HbA PSA Complexity logKeq Lipinski GI50
Actinomycin D 3053 Intercalation 1255 1.6 5 18 356 3030 5.38 2 8.7
Bleomycin 125066 Intercalation 1416 -1.9 20 30 627 2580 5.57 1 5.9
Chartreusin 5159 Intercalation 641 2.6 5 14 200 1150 5.45 2 5.7
Chromomycin 58514 minor-groove 1185 -0.6 8 26 359 2480 4.41 1 8.3
Daunorubicin 82151 intercalation 528 0.1 5 11 186 960 6.65 2 7.1
Distamycin A 82150 minor-groove 482 0.2 6 9 181 825 6.89 3 4.1
Doxorubicin 123127 intercalation 544 -0.5 6 12 206 977 6.30 1 7.2
Echinomycin 526417 bis-intercalation 1101 2.5 4 16 302 2200 5.52 2 8.1
Elsamicin A 369327 intercalation 654 2.9 5 14 206 1210 6.54 2 7.5
Epirubicin 256942 intercalation 544 -0.5 6 12 206 977 6.57 2 6.7
Ethidium 268986 intercalation 394 4.3 2 3 56 419 4.90 4 5.5
m-AMSA 249992 intercalation 394 3.8 2 6 80 601 4.30 4 6.2
Mitoxantrone 301739 intercalation 445 -3.1 8 10 163 571 6.78 3 7.2
Mithramycin A 24559 minor-groove 1085 -0.4 11 24 358 1940 5.08 1 7.9
Netropsin 3067 minor-groove 431 -1.7 7 10 211 723 6.40 2 4.0
a Mw: Molecular weight, XlogP: partition coefficient that measures the differential solubility of a compound in two solvents, HbD: number of hydrogen bond
donors in the structure, HbA: number of hydrogen bond acceptors, PSA: polar surface area (in Å2). Complexity: a rough estimate of how complicated a
structure is. Both the elements contained and the displayed structural features including symmetry are considered. logKeq: logarithmic-transformed
equilibrium binding constant for a drug-DNA complex (Keq in M-1). Lipinski: Lipinski’s score, the rule-of-five value used to measure bioavailability. GI50 is
used in place of -log(GI50), the negative logarithm of the average drug concentration that inhibits cell growth in the NCI-60 cell lines (August 2008 data) as a
measure of cytotoxicity or cytostasis.
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Table 2. Results of the Shapiro-Wilk normality test(a)
W-Statistic df p
MW 0.827 15 0.008
XlogP 0.951 15 0.542
HbD 0.767 15 0.001
HbA 0.933 15 0.298
PSA 0.862 15 0.026
Complexity 0.873 15 0.038
logKeq 0.915 15 0.163
Lipinski 0.847 15 0.016
GI50 0.960 15 0.697
(a) Molecular descriptors were considered to pass the normality test if p > 0.01
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Table 3. Calculated Pearson and Spearman’s rcorrelation coefficients between each molecular descriptor and log Keq.
All Drugs Intercalators ‘M-region’
Pearson p Spearman’s pa Pearson p Spearman’s p Pearson p Spearman’s p
Mw -0.396 7.22 x 10-2 -0.177 2.64 x 10-1 -0.096 3.96 x 10-1 0.073 4.20 x 10-1 -0.909 8.72 x 10-4 -0.857 3.27 x 10-3
XlogP -0.461 4.20 x 10-2 -0.388 7.66 x 10-2 -0.662 1.85 x 10-2 -0.699 1.20 x 10-2 -0.118 3.91 x 10-1 0.000 5.00 x 10-1
HbD 0.047 4.34 x 10-1 0.252 1.83 x 10-1 0.189 3.01 x 10-1 0.636 2.40 x 10-2 -0.368 1.85 x 10-1 -0.258 2.69 x 10-1
HbA -0.272 1.63 x 10-1 -0.244 1.91 x 10-1 0.143 3.50 x 10-1 0.049 4.47 x 10-1 -0.955 1.11 x 10-4 -0.976 1.66 x 10-5
PSA -0.151 2.96 x 10-1 -0.211 2.25 x 10-1 0.079 4.10 x 10-1 0.141 3.50 x 10-1 -0.950 1.47 x 10-4 -0.994 1.00 x 10-6
Complexity -0.373 8.56 x 10-2 -0.252 1.82 x 10-1 -0.088 4.00 x 10-1 -0.067 4.30 x 10-1 -0.844 4.18 x 10-3 -0.857 3.27 x 10-3
a Significance level (actual p values)
25
Table 4. Equations used to predict logKeq values for DNA-binding drugsa. The predictive equations are presented for the three sets of drugs
analyzed (All DNA-binding drugs, Intercalators and ‘M-region’ compounds) described in the main textb.
Predictive equation r p AdR2
All drugs log Keq = −0.255(±0.100)XlogP − 0.003(±0.002)PSA + 6.603(±0.465) 0.603 6.6 x 10-2 0.258
All drugs log Keq = −0.181(±0.097)XlogP + 5.895(±0.215) 0.461 8.4 x 10-2 0.152
Intercalators log Keq = −0.225(±0.090)XlogP + 6.054(±0.229) 0.662 3.7 x 10-2 0.368
‘M-region’ log Keq = 0.128(±0.067)XlogP − 0.178(±0.020)HbA + 0.173(±0.066)HbD + 7.577(±0.298) 0.984 2.0 x 10-3 0.944
‘M-region’ log Keq = −0.138(±0.190)HbA + 8.090(±0.303) 0.955 2.2 x 10-4 0.897
aObtained by multiple regression analysis, in which molecular descriptors showing multicollinearity were discarded (see the main text for
details). The predictive equations displayed are those statistically “more significant” for each set of predictors (actual p values, ANOVA test, are
shown in the Table), r is the correlation coefficient of the linear fit, AdR2 is the fraction of the variance in logKeq that is explained (predicted) by
the model, corrected for the number the variables in the model, as described in Methods.
bThe cases (drugs) used in the calculations for each set were 15, 10 and 8 respectively.
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Table 5. Equations used to predict GI50 values for DNA-binding drugsa. The predictive equations are presented for the three sets of drugs
analyzed (All 15 drugs, Intercalators and ‘M-region’ compounds) described in the main textb.
Predictive equation r p AdR2
All drugsc GI50 = 0.002(±0.001)Complexity − 0.008(±0.004)PSA + 5.688(±0.591) 0.713 1.4 x 10-2 0.426
Intercalators GI50 = 0.742(±0.219)logKeq + 0.002(±0.000)Complexity - 0.008(±0.002)PSA+ 1.977(±1.319) 0.894 1.6 x 10-2 0.700
‘M-region’ GI50 = 0.021(±0.102)logKeq + 0.001(±0.000)Complexity + 6.478(±0.746) 0.984 1.8 x 10-4 0.955
a Obtained by multiple regression analysis. The predictive equations displayed are those statistically more significant for each set of predictors
(actual p values, ANOVA test, are shown in the Table). Other details as in legend to Table 4.
bThe cases (drugs) used in the calculations for each set were 15, 10 and 8 respectively.
c logKeq was not a significant predictor for GI50 for the set that contains the 15 (all) drugs.
27
Additional files:
Additional File 1.
File Format: PDF
Title: Additional File 1
Description: Pearson correlations (r) and significance levels (p-values) calculated
between all molecular descriptors and GI50 values
Additional File 2.
File Format: PDF
Title: Additional File 2
Description: Spearman's ρ correlations and significance levels (p-values) calculated
between all molecular descriptors and GI50 values.
Additional File 3.
File Format: PDF
Title: Data outputs obtained in the multiple regression analyses to predict logKeq
using molecular descriptors.
Description: Data are presented for the three subsets of drugs: DNA-binding (all)
drugs, intercalators, and ‘M-region’ compounds. Equations used to predict logKeq are
shown in Table 4.
Additional File 4.
File Format: PDF
Title: Data ouputs generated by the principal component analyses of the molecular
descriptors used to predict logKeq.
Description: Data are presented for the three subsets of drugs: DNA-binding (all)
drugs, intercalators and ‘M-region’ compounds.
Additional File 5.
File Format: PDF
28
Title: Data outputs obtained in the multiple regression analyses to predict cytotoxicity
(GI50) using molecular descriptors and the drug-DNA equilibrium binding constant
(logKeq).
Description: Data are presented for the three subsets of drugs: DNA-binding (all)
drugs, intercalators, and ‘M-region’ compounds. Equations used to predict GI50 are
shown in Table 5.
Additional File 6.
File Format: PDF
Title: Data outputs generated by the principal component analyses of the molecular
descriptors and the drug-DNA equilibrium binding constant (logKeq) used to predict
cytotoxicity (GI50).
Description: Data are presented for the three subsets of drugs: DNA-binding (all)
drugs, intercalators and ‘M-region’ compounds.
Figure 1
Figure 2
Figure 3
Figure 4
Additional files provided with this submission:
Additional file 1: additional file 1.pdf, 76K
http://www.biomedcentral.com/imedia/1339574625257469/supp1.pdf
Additional file 2: additional file 2.pdf, 79K
http://www.biomedcentral.com/imedia/1258989067257469/supp2.pdf
Additional file 3: additional file 3.pdf, 209K
http://www.biomedcentral.com/imedia/1796068188257469/supp3.pdf
Additional file 4: additional file 4.pdf, 107K
http://www.biomedcentral.com/imedia/8850601932574693/supp4.pdf
Additional file 5: additional file 5.pdf, 112K
http://www.biomedcentral.com/imedia/6132781732574693/supp5.pdf
Additional file 6: additional file 6.pdf, 133K
http://www.biomedcentral.com/imedia/7551979622574693/supp6.pdf
